Table 3 Summary of NRF2 associated miRNAs in cancer.
From: Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression
Name | Associated cancer type | Target | Influence to NRF2 | Model of evidence | Reference |
---|---|---|---|---|---|
miR-141 | Hepatocellular carcinoma, ovarian cancer | KEAP1 | Up | Cell culture | |
miR-23a | Leukemic | KEAP1 | Up | Cell culture, animal models | |
miR-432 | Esophageal cancer | KEAP1 | Up | Cell culture | |
miR-7 | Neuroblastoma cells | KEAP1 | Up | Cell culture | |
miR-200a | Breast cancer, esophageal cancer, hepatocellular carcinoma, and pancreatic adenocarcinomas | KEAP1, | Up | Cell culture, animal models | |
miR-155 | Lung cancer | NRF2 | Up | Cell culture | |
miR-101 | Hepatocellular carcinoma, prostate cancer | NRF2, SOD1 | Up/Down | Cell culture, animal models | |
miR-1 | Lung cancer, prostate cancer | NRF2, SOD1 | Up/Inhibited by NRF2 | Cell culture, animal models | |
miR-206 | Lung cancer, prostate cancer | NRF2, SOD1 | Up/Inhibited by NRF2 | Cell culture, animal models | |
miR-148b | Endometrial cancer | ERMP1 | Down | Cell culture | |
miR-129 | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-129-5a | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-129-5p | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-142 | Esophageal cancer | NRF2 | Down | Cell culture | |
miR-144 | Hepatocellular carcinoma, leukemia, hepatocellular carcinoma, neuroblastoma | NRF2 | Down | Cell culture | |
miR-144-3p | Melanoma, lung cancer, and acute myeloid leukemia | NRF2 | Down | Cell culture | |
miR-153 | Neuroblastoma, breast cancer, and oral squamous cell carcinoma | NRF2 | Down | Cell culture | |
miR-200c | Lung cancer | NRF2 | Down | Cell culture, animal models | |
miR-212-3p | Melanoma | NRF2 | Down | Cell culture | |
miR-23b-3p | Melanoma | NRF2 | Down | Cell culture | |
miR-27 | Neuroblastoma | NRF2 | Down | Cell culture, animal models | |
miR-28 | Breast cancer, esophageal cancer | NRF2 | Down | Cell culture | |
miR-340 | Hepatocellular carcinoma, esophageal cancer | NRF2 | Down | Cell culture | |
miR-34a | Breast cancer, colon cancer, ovarian cancer, and lung cancer | NRF2 | Down | Cell culture | |
miR-450 | Esophageal cancer | NRF2 | Down | Cell culture | |
miR-450a | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-495 | Nonsmall-cell lung cancer | NRF2 | Down | Cell culture | |
miR-507 | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-634 | Esophageal cancer | NRF2 | Down | Cell culture, animal models | |
miR-93 | Pancreatic adenocarcinomas, breast cancer | NRF2 | Down | Cell culture, animal models | |
miR-93-5p | Melanoma | NRF2 | Down | Clinical samples | |
miR-125b | Acute myelocytic leukemia, oral squamous cell carcinoma, and renal cancer | NRF2 | Down/Induced by NRF2 | Cell culture, animal models | |
miR-181c | Colorectal cancer | – | Inhibited by NRF2 | Cell culture, animal models | |
miR-378 | Mucoepidermoid carcinoma | – | Inhibited by NRF2 | Cell culture, animal models | |
miR-122 | Hepatocellular carcinoma | – | Inhibited by NRF2 | Cell culture | |
miR-17-5p | Multiple myeloma | – | Inhibited by NRF2 | Cell culture, animal models | |
miR-29B1 | Acute myelocytic leukemia | – | Induced by NRF2 | Cell culture | |
miR-129-3p | Hepatocellular carcinoma | – | Induced by NRF2 | Cell culture, animal models | |
miR-380-3p | Neuroblastoma | – | Induced by NRF2 | Cell culture, animal models |